By Maggie Fick STEVENAGE, England (Reuters) – GSK’s chief scientist says an overhaul of the drugmaker’s R&D unit has begun delivering results – citing an RSV vaccine and promising hepatitis B and asthma treatments – and pledged a tighter focus than his predecessor on infectious disease
Latest posts by Crypto Editor (see all)
- FP Markets Webinar for January 31: Explore TradingView with FP Markets Market Analyst Aaron Hill - January 18, 2024
- Crude Oil Price Forecast – Crude Oil Continues to Bounce Around - January 18, 2024
- AUD/USD Forecast – Australian Dollar Continues to Test Support - January 18, 2024